Orally-taken meal supplementing medicament for treating osteoarthritis

A dietary supplement, osteoarthritis technology, applied in the fields of application, food science, food ingredients, etc., can solve the problems of increasing the pain of patients, not describing the use of magnesium and its compounds, associated with joint infections, etc., achieving low cost and high cost. Selective, good compliance effects

CN108719998AInactive Publication Date: 2018-11-02XIANGYA HOSPITAL CENT SOUTH UNIV
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2018-11-02
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses orally-taken meal supplementing medicament for treating osteoarthritis. The orally-taken meal supplementing medicament for treating osteoarthritis contains magnesium, so that the cartilage damage degree of a rat OA model can be relieved, and the orally-taken meal supplementing medicament for treating osteoarthritis is effective for reducing cartilage matrix degradation, reducing cartilage surface damage degree, and relieving cartilage degrading.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to an oral dietary supplement for the treatment of osteoarthritis. technical background

[0002] Osteoarthritis (OA) is a joint degenerative disease characterized by degeneration of articular cartilage, subchondral bone sclerosis and osteophyte formation, and is mainly characterized by joint pain, limited mobility and joint deformation after activities. Clinical manifestations, often involving weight-bearing joints. Epidemiological surveys in my country show that the prevalence of OA in people over 65 years old exceeds 50%, about 80% of OA patients have a certain degree of movement limitation, and 25% of OA patients are significantly affected in daily life. The cost of treating OA may be as high as 150 billion yuan. Among people over 50 years old in the United States, the disability rate of OA ranks second among all diseases, second only to cardiovascular diseases. With the increase of aging population and obese populati...

Examples

Embodiment Construction

[0029] Example Magnesium and its compound Dietary Supplement Pharmacy Animal Experiment Verification of Curative Effects on Osteoarthritis

[0030] 1 Experimental materials and methods

[0031] 1.1 Drugs and reagents

[0032] Ordinary rat feed (magnesium element content is 0.255g / kg)

[0033] Add the rat feed (magnesium element content is 2.55g / kg) of magnesia dietary supplement medicament

[0034] 1.2 Experimental animals

[0035] Adult male Sprague-Dawley (SD) rats (about 500g in weight)

[0036] 1.3 Experimental method

[0037] 1.3.1 Surgical Modeling

[0038] Knee OA model was constructed by right knee medial collateral ligament, anterior cruciate ligament transection and medial meniscectomy. This model has been validated to induce knee osteoarthritis and represents a good example of experimental degenerative osteoarthritis for pharmacological evaluation of tested drugs.

[0039] 1.3.2 Grouping and administration

[0040] After modeling, the rats were randomly divi...